Core Viewpoint - The company has repurchased a total of 7.627 million shares under its share buyback authorization from October 21, 2025, to December 17, 2025, indicating confidence in its long-term growth and market performance [1] Group 1 - The board believes the current stock price is below its true value and does not reflect the company's business prospects adequately [1] - The share buyback plan has been extended until the conclusion of the next annual general meeting, demonstrating the board's commitment to shareholder interests [1] - The board has been informed that Yijie Biotechnology Holdings Limited and its concert parties have cumulatively purchased 335,000 shares between November 6, 2025, and December 17, 2025, increasing their total holdings to 218,283,730 shares, representing approximately 38.2% of the total issued shares [1] Group 2 - The board views the increase in shareholding by major shareholders as a sign of confidence in the company's future and growth potential, as well as recognition of its long-term investment value [1]

Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (02171.HK) announced that the Yijie Biotechnology Holdings Limited and its concerted parties have cumulatively purchased 335,000 shares between November 6, 2025, and December 17, 2025, increasing their stake to approximately 38.2% of the total issued shares excluding treasury shares as of the announcement date [1]. Group 1 - Yijie Biotechnology Holdings Limited and its concerted parties are collectively referred to as the "Yijie Concerted Action Group" [1]. - The total number of shares held by the Yijie Concerted Action Group after the purchase is 218,283,730 shares [1]. - The purchase of shares indicates a significant increase in ownership percentage, reflecting confidence in the company [1].

香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本公告的內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CARsgen Therapeutics Holdings Limited 科濟藥業控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2171） 自願公告 本公司購回股份及主要股東增持股份 本公告由科濟藥業控股有限公司（「本公司」，連同其附屬公司及併表聯屬實體統 稱「本集團」或「科濟藥業」）自願作出。 本公司購回股份 茲提述(1)本公司日期為2025年5月13日的自願公告，內容有關股份購回計劃（「過 往股份購回計劃」），即自2025年5月8日起的150個香港交易日內在公開市場上購 回不超過本公司股份（「股份」）1%的股份；(2)本公司股東於2025年5月22日舉行 的股東週年大會上授予的股份購回一般授權，據此最多可購回於有關決議案獲 通過之日已發行股份總數之10%，即最多57,543,590股股份（「2025年股份購回授 權」）；及(3)本公司日期為2025年11月13日 ...

Group 1 - The core point of the article is that non-executive director Guo Huaqing increased his stake in Kintor Pharmaceutical (stock code: 02171) by purchasing 30,000 shares at a price of HKD 14.98 per share, totaling HKD 449,400 [1] - After the purchase, Guo Huaqing's total shareholding in Kintor Pharmaceutical reached approximately 224 million shares, representing a 38.75% ownership stake [1]

格隆汇12月17日丨科济药业-B(02171.HK)公告，12月17日耗资673.7万港元回购46.6万股。 ...

智通财经APP讯，科济药业-B(02171)发布公告，于2025年12月17日斥资673.7万港元回购46.6万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 科濟藥業控股有限公司 呈交日期： 2025年12月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02171 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫 ...

Core Viewpoint - Company Kojis Pharmaceuticals (02171) announced a share buyback plan, intending to repurchase 1.01 million shares for a total cost of HKD 14.762 million, scheduled for December 16, 2025 [1] Group 1 - The total amount allocated for the share buyback is HKD 14.762 million [1] - The number of shares to be repurchased is 1.01 million [1] - The buyback is set to occur on December 16, 2025 [1]

智通财经APP讯，科济药业-B(02171)发布公告，于2025年12月16日斥资1476.2万港元回购101万股。 ...

格隆汇12月16日丨科济药业-B(02171.HK)公告，12月16日耗资1476.2万港元回购101万股。 ...